Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), filed a Form 4 on November 3, 2026, disclosing a series of option exercises and open-market sales of Class A Ordinary Shares conducted between October 30 and November 3, 2026, all pursuant to a 10b5-1 plan.

Key Highlights

  • 10b5-1 plan: All transactions were effected pursuant to a 10b5-1 plan executed by Patel on July 30, 2026.
  • Options exercised: Patel exercised share options covering a total of 231,237 Class A Ordinary Shares across four transactions at exercise prices of $8.83 and $17.92.
  • Shares sold: A total of 481,594 Class A Ordinary Shares were disposed of (transaction code S) through the Anglia 2013 Revocable Trust between October 30 and November 3, 2026, at weighted average prices ranging from approximately $90.77 to $98.16.
  • Remaining indirect holdings: Following all reported transactions, Patel beneficially owned 780,037 shares indirectly through the Anglia 2013 Revocable Trust, plus 76,174 through the Patel Family Irrevocable Trust of 2025, and 109,795 through the Marina 2016 Irrevocable Trust.
  • Options fully exercised: The $8.83 share option position was reduced to 0 following the November 3, 2026 exercise; the $17.92 share option position had 145,763 remaining after the November 3 exercise.
  • Ownership form: All reported share transactions were held indirectly through the Anglia 2013 Revocable Trust; no direct share holdings are reported in the filing.

Patel's Multi-Day Option Exercise and Share Sale Activity at Kiniksa

According to the filing, Sanj K Patel, serving as Chairman and CEO of Kiniksa Pharmaceuticals International, plc, carried out a series of transactions across three trading days. On October 30, 2026, Patel exercised options covering 47,530 Class A Ordinary Shares at $8.83 per share and subsequently sold 92,891 shares in multiple tranches at weighted average prices between $92.01 and $98.16, all held through the Anglia 2013 Revocable Trust. Following these disposals, the trust's beneficial ownership stood at 905,933 shares.

On November 2, 2026, the filing reports an additional option exercise of 53,381 shares at $8.83 per share and sales of 89,333 shares at weighted average prices ranging from $91.03 to $93.97, reducing the trust's holdings to 869,881 shares. On November 3, 2026, two separate option exercises were reported: 89,089 shares at $8.83 (exhausting that option grant) and 41,237 shares at $17.92. Sales on November 3 totaled 219,170 shares at weighted average prices between $90.77 and $94.25, bringing the Anglia 2013 Revocable Trust's position to 780,037 shares, the filing disclosed.

The filing notes that each sale transaction "was executed in multiple trades through a broker-dealer" and that prices reported reflect weighted averages. Full per-trade pricing is available to SEC staff upon request. In addition to the Anglia 2013 Revocable Trust holdings, the filing reports 76,174 shares held by the Patel Family Irrevocable Trust of 2025 and 109,795 shares held by the Marina 2016 Irrevocable Trust, u/d/t June 23, 2016, with no transactions reported for those two trusts.

What Was Disclosed

The filing disclosed option exercises and open-market share sales by Kiniksa Pharmaceuticals International's Chairman and CEO, Sanj K Patel, across October 30 through November 3, 2026, all executed under a 10b5-1 plan established July 30, 2026, with shares held indirectly through trust structures.